The Company has enclosed herewith Annual Secretarial Complince Report for the yaer ended 31.03.2026.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krebs Biochemicals submitted its Annual Secretarial Compliance Report for FY 2025-26, audited by DSMR & Associates. The report highlights two key compliance deviations: (1) 20,400 equity shares belonging to promoters remain undematerialized due to an ongoing court case (sub-judice), violating Regulation 31(2) of SEBI LODR which requires 100% promoter holding in demat form. This issue persists from the previous year with no penalty imposed. (2) The company appointed Independent Directors after the completion of tenure of the previous Independent Director (between Jan-Feb 2025), resulting in a brief non-compliance with Regulation 17(1)(b). BSE and NSE each imposed penalties of Rs. 1,94,700, which the company has paid. All other areas including secretarial standards, insider trading compliance, related party transactions, document preservation, and performance evaluation were found satisfactory.
The ongoing court case regarding promoter shares creates a minor compliance risk. The company has paid penalties for delayed Independent Director appointment but has since corrected the issue. The stock is listed on BSE (524518) and NSE (KREBSBIO).